drugset / Trial / NCT01747798

Auranofin in Treating Patients With Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

NCT01747798

Phase 0 Completed 10 enrolled Mayo Clinic
NaSingle-groupOpen-labelTreatment

Summary

This pilot clinical trial studies auranofin in treating patients with epithelial ovarian, primary peritoneal, or fallopian tube cancer. Immunosuppressive therapy, such as auranofin, may be an effective treatment for epithelial ovarian, primary peritoneal, or fallopian tube cancer.

Timeline

Start
2012-11-02
Primary completion
2014-01-10
Completion
2015-04-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Auranofin Small molecule Oral